Spherix Incorporated , an intellectual property company, owns, develops, acquires, and monetizes patented and unpatented intellectual properties. The company owns approximately 290 patents and patent applications. Its patent portfolio includes the U.S. and foreign patents and pending patent applications in the wireless communications and telecommunication sectors, including data, optical and voice technology, antenna technology, Wi-Fi, base station functionality, and cellular. Spherix Incorporated was founded in 1967 and is based in New York, New York.

  • University of Maryland, Baltimore Grants Spherix Exclusive Option to License Anthrax Based Ovarian Cancer Drug PrAg-PAS
    on September 17, 2019 at 5:30 pm

    The Option includes rights to U.S. Patent Application Serial No. 15/747,255, which is currently under active examination at the U.S. Patent and Trademark Office.  Under the Option, Spherix has until early December of 2019 to complete its due diligence and execute a license agreement for commercial development.

  • Spherix is Granted Exclusive Option to License Anticancer Drug from the University of Kentucky
    on September 11, 2019 at 5:00 pm

    NEW YORK, Sept. 11, 2019 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that the Company has executed an exclusive option agreement ("Option") with the University of Kentucky (UK) related to its anticancer drug designated G4-1, a novel proteasome inhibitor. Spherix's Option includes two issued patents, United States Patent Nos. Under the Option, Spherix has until late November to complete its due diligence and execute a license agreement for commercial development.

  • Spherix Announces Results of Special Meeting of Shareholders
    on September 9, 2019 at 12:00 pm

    At the Meeting, the Company's shareholders approved the issuance of shares of our Common Stock, including shares of our common stock underlying Series L convertible preferred stock, to be issued by us pursuant to the terms of that certain Asset Purchase Agreement, dated May 15, 2019, by and between the Company and CBM BioPharma, Inc., as amended by Amendment No. 1 to the Asset Purchase Agreement, dated May 30, 2019, in an amount equal to or in excess of 20% of our common stock outstanding before the issuance of such common stock and such Series L convertible preferred stock (including upon the operation of anti-dilution provisions contained in such Series L convertible preferred stock). Shareholders also approved the amendment to the Company's Amended and Restated Certificate of Incorporation to decrease the number of authorized shares of common stock from 100,000,000 to 99,000,000.

  • Spherix Urges Shareholders to Approve Purchase of CBM BioPharma, Inc. Assets at Special Meeting
    on August 19, 2019 at 12:00 pm

    In advance of our Special Meeting on September 5th, I write to update you on certain developments and to encourage you to vote in favor of the proposals recommended by the Board of Directors and set forth in the Special Meeting Proxy. The acquisition of the CBM BioPharma, Inc. ("CBM") pharmaceutical assets is an integral step in building Spherix into a cutting edge pharmaceutical company.  It also builds upon the success we have already realized as a part of the Company's transformation.  Two years ago, Spherix made an investment in Hoth Therapeutics, Inc., which is now estimated to be worth over $10,000,000.  In our effort to deliver value to our shareholders and to continue the transformation at Spherix, the Board intends to propose a special dividend of One Hundred Thousand shares (100,000) of Hoth stock.

  • United States Patent & Trademark Office Allows Patent Claims for CBM BioPharma, Inc.'s Patent Application for Pancreatic Cancer Treatment
    on June 26, 2019 at 12:00 pm

    CBM Bolsters Intellectual Property Asset Portfolio NEW YORK , June 26, 2019 /PRNewswire/ -- CBM BioPharma Inc. ("CBM") today announced that the United States Patent & Trademark Office (USPTO) ...

  • Spherix Files Preliminary Proxy Statement Advancing the Planned Acquisition of Assets of CBM BioPharma, Inc.
    on June 19, 2019 at 12:00 pm

    NEW YORK, June 19, 2019 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that it has filed a Preliminary Proxy Statement with the Securities and Exchange Commission and announced a Special Meeting of Stockholders related to approving various items related to the proposed and previously announced acquisition of substantially all of the assets of CBM BioPharma, Inc. ("CBM"). The acquisition of the CBM assets constitutes another step in Spherix's continued transformation into an innovative pharmaceutical company with pioneering drugs and treatments focused on the development and commercialization of oncology therapeutics. CBM is a privately held pharmaceutical company with exclusive drug development rights from world renowned partners like Wake Forest University and University of Texas.

  • Spherix Inc. (NasdaqCM: SPEX) Trading Below Book Value; Diversified Asset Base Adds Value
    on June 11, 2019 at 2:10 pm

    MIAMI BEACH, FL / ACCESSWIRE / June 11, 2019 / Emerging stocks rarely provide more than a single compelling reason for investment. Having completed a recapitalization in May of 2019 that leaves SPEX with just over two million shares outstanding, the company's strategy to identify and invest in cutting-edge technology is already proving to be a profitable business model for SPEX.

  • StockLab Reports: By the Numbers
    on June 6, 2019 at 1:00 pm

    LAS VEGAS, NV / ACCESSWIRE / June 6, 2019 / In October of last year, StockLab's editorial team was introduced to Spherix Incorporated (SPEX). Frankly, it's tough to top a Spherix acquisition target restoring mobility to a nearly paralyzed rodent but last week's quarterly report perhaps rivals the moving mouse insofar as financial statements go. The Company has total assets of $11,937,000.

  • Spherix Reports First Quarter 2019 Results of $11,937,000 in Assets and $982,000 in Liabilities
    on May 16, 2019 at 12:00 pm

    Agreement to Acquire Assets of CBM BioPharma, Inc. In addition, the Company announced that it purchased a 20% shareholder's stake in CBM along with certain interests in DatChat, Inc. Spherix was successful in acquiring these interests in CBM at a substantial discount to CBM's valuation.  The 20% shareholder stake in CBM will give Spherix the ability to participate in any dividends declared by CBM in the future.

  • SmallCap Sentinel: One-on-One with Spherix CEO, Anthony Hayes
    on April 10, 2019 at 11:00 am

    ORLANDO, FL / ACCESSWIRE / April 10, 2019 / In today's issue of SmalCap Sentinel, we get the opportunity to virtually sit down with Spherix Incorporated (SPEX) CEO, Anthony Hayes. It has been an eventful year for Hayes and Spherix, much of which Hayes covered in a wide-ranging recent shareholderletter.


What's Your Role?*



Company Description*



Spherix Incorporated

One Rockefeller Plaza
11th Floor
New York, NY 10020

+1 (703) 992-9325


September 2019
« Aug    

©2019 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account